MaxCyte and Ori Biotech have entered a strategic collaboration to enhance manufacturing efficiency and scalability for autologous cellular therapies. The partnership combines MaxCyte’s clinical-scale electroporation technology with Ori’s automated cell culture and fluid handling platform, aiming to improve yield and shorten production timelines. Initial assessments will target CRISPR knock-in engineering of CD19 CAR T cells, offering a synergistic toolkit to accelerate gene-edited cell therapy availability and commercial viability, reflecting the growing emphasis on modular and scalable biomanufacturing in advanced therapeutics.